Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Its research pipeline includes various investigational medicines.
The company has license agreements with LFB BiotechnologiesS. A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.
The company was incorporated in 1993 and is based in Morrisville, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | 0.15 Increased by +250.00% | 0.09 Increased by +66.67% |
| Nov 4, 24 | 0.02 Decreased by -97.26% | 0.03 Decreased by -33.33% |
| Aug 6, 24 | 0.04 Increased by +111.76% | -0.05 Increased by +180.00% |
| May 1, 24 | -0.07 Increased by +75.00% | -0.04 Decreased by -75.00% |
| Feb 28, 24 | -0.10 Increased by +74.36% | -0.10 |
| Nov 1, 23 | 0.73 Increased by +380.77% | 0.12 Increased by +508.33% |
| Aug 1, 23 | -0.34 Decreased by -13.33% | -0.25 Decreased by -36.00% |
| May 1, 23 | -0.28 Increased by +45.10% | -0.37 Increased by +24.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 108.19 M Increased by +146.04% | 23.33 M Increased by +261.84% | Increased by +21.57% Increased by +165.78% |
| Sep 30, 24 | 83.88 M Decreased by -49.41% | 3.88 M Decreased by -96.59% | Increased by +4.63% Decreased by -93.27% |
| Jun 30, 24 | 73.47 M Increased by +357.05% | 6.88 M Increased by +114.45% | Increased by +9.36% Increased by +103.16% |
| Mar 31, 24 | 63.47 M Increased by +713.46% | -10.71 M Increased by +72.28% | Decreased by -16.87% Increased by +96.59% |
| Dec 31, 23 | 43.97 M Increased by +54.86 K% | -14.42 M Increased by +73.27% | Decreased by -32.79% Increased by +99.95% |
| Sep 30, 23 | 165.81 M Increased by +176.30 K% | 113.93 M Increased by +410.66% | Increased by +68.71% Increased by +100.18% |
| Jun 30, 23 | 16.07 M Increased by +2.61 K% | -47.61 M Decreased by -13.14% | Decreased by -296.19% Increased by +95.82% |
| Mar 31, 23 | 7.80 M Increased by +287.05% | -38.63 M Increased by +45.71% | Decreased by -495.04% Increased by +85.97% |